ALK and non-small cell lung carcinoma: In a clinical trial of first-line platinum-based chemotherapy versus chemotherapy plus pembrolizumab for NSCLC without EGFR or ALK mutations, carboplatin and cisplatin were used in 72.3% and 27.8% of cases, respectively [19].